|
Effects of drotrecogin on mortality in National Registry data |
||||
| Registry/Trial |
Country |
Patients treated with DrotAA (% of cases) |
ARR |
OR (95% CI) |
|
|
||||
| PROWESS |
International |
1,690 |
6.1% |
0.8 (0.69 to 0.94) |
| UK [21] |
1,245 (6.3%) |
0.75 (0.68 to 0.83) |
||
| Poland [22] |
302 (9.3%) |
17.3% |
||
| PROGRESS |
International [20] |
882 (7%) |
0.75 (0.63 to 0.9) |
|
| Belgium [24] |
430 |
12.8% |
0.61 (0.40 to 0.92) |
|
|
ARR, absolute risk reduction; CI, confidence interval; DrotAA, drotrecogin alfa (activated); OR, odds ratio; PROGRESS, Promoting Global Research Excellence in Severe Sepsis; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis. | ||||
Camporota and Wyncoll Critical Care 2007 11(Suppl 5):S7 doi:10.1186/cc6158 |
||||